Prostate cancer genetic★γ♦ testing prognosis risk assessment system (Pros∑®♣tatype® testing system)

The world's leading

A global leader: Precision medical findings fr€≠om the Nobel institution urology professor a"σ÷>t the Karolinska Institute team fo≠ &βr nearly 20 years
1. The global leader i♥♣n genetic testing for prostate cancer pro'π÷gnostic risk assessment sys∞>"☆tem
2. Use the world's oα>nly course of treatment δ€as a real patient Referenc♦ e risk assessment system
3. Research and development achievements oε><γf academicians of the Royal Swedish Academ¶βy of Engineering (IVA)
4. Combined genetic testing factors sign∑¥‍ificantly improve the accuracy o∑δ÷↔f prognostic scores
5. Revolutionarily provide more scientif★®ic treatment options for p≤‍©atients with prostate cancer

Prostate cancer clinical σε♦background

1. Prostate cancer is oneσ₽ of the highest incidence of male cancer in Weste∏π∞₽rn developed countrie'±±λs in Europe, America a®λ®nd Europe;
2. With the improvement of economic ↓±¶level and residents' l"≤iving standards in China, its incid♥₹∑ence rate is also rapidly increasing. I‌✔t is expected that it will enter Chines∞λe males within ten years The top thr ↓•₩ee of malignant tumors;
3. Although the incidence ★≥↑of prostate cancer is high∑↑≤↑, not all cancer subtypes are mali∑£®>gnant and fatal, and most prostate cancer subtσ‌ypes (nearly 80%) are rela♦©tively benign rather than fatal;
4. Studies have shown ≈★δ that 7 out of 10 of them are over-treφ ated or under-treated♠₽≈γ, mainly due to the low ac≠"curacy of clinical prognostic scores.
5. The survival rate of prostate cancer patients ®→‌in developed countries is m☆±'ore than 98% over 5 years, while in China Terri✔ σble 50%.

Prostate cancer treatmen✔Ω←t in the world

Prostatype®

Our prostate cancer ♠βrisk prognosis detection syste&♦≤m
How does it improve forecast accuracy?
What clinical problem™✘←s can be solved?

Testing process

Product advantages

1. The key technology involved §₹in this project has a↔₽pplied for an internat← ‌ional invention patent, whi"₽ch has been approved in Sweden£±, Japan, China and the±&§ United States.
2. Using the combination o&£f the world's leading genetic technology and€♣ biological big data, revolutionaryly provide a✘≈↓§ccurate personalized treatment programs for pro★σ∏state patients, and greatly improve the accu'≠racy of patient prognosis rε&♣'isk assessment.
3. This project is based on the advantages of Sw'±eden's first and the most≤ ₹" complete clinical samples and follow-up data i§←n the world, and completely tracks← the patient's entire process.
4. The database of this project is com←±¥posed of 600 real cases, and the patient's clinεεical data and genetic test data ₹ are completely collected. The software that mΩφeets the clinical registration s♠'tandards was developed using mathematical models×≤✘> and statistical analysis. The software's prostε♣¶εate cancer risk classification Th¥→e algorithm and cancer risk index are glob""γally unique and have passed CE certification.φ≥
5. This project is currently theγ↑←£ only testing system in the ↕π¶world that does not need to send patient sample✔ ✘s to a special labor✘×♠atory for testing, and can be di≈ ↕βrectly used in the clinic for doctors to use.
6. Prostatype can imφ®prove the accuracy of prognosis judgment↑♣§ of survival time by 25π≈♦%, especially for patients with medium-risk α‍ patients who are most difficult to cho•β₩×ose treatment options.

Prognostic system compared with Europ' ean standards EAU and CARPA

Comparison of international mainstream products₹±÷

Company name	Chundsell Medicals (S® weden)	Genomic Health (United States)	Myriad GeneDcs (United States)	MetamarksGeneDcs (Unit♠♣ed States)	Bostwick Laborator ies (United States)
product name	Prostatype®Test System	Oncotype Prostate DX	Prolaris	Promark	ProstaVysion
Detection gene	RNA expression levels of 4 related genesδ→	17 related gene RNA expression levels	46 related gene RNA expression levels	8 related protein expression levels	3 related gene mutations
Gene type	Stem cell gene	Proliferation gene	Proliferation gene	Proliferation gene	Proliferation gene
Clinical application	Treatment and survival pr∏±φognosis	Prognosis of treatment, refer ↓₹↑to NCNN	Treatment prognosis, refer to CAPRA	Prognosis of treatment, refer to NC€←♦NN	No
Scientific verification	3 articles	2 articles	2 articles	3 articles	PTEN / ERG related report☆σ₩s
Laboratory type	Local molecular pathology ↕ experiment	CLIA Standardized Laboratory	CLIA Standardized Laboratory	CLIA Standardized Labor✔®atory	CLIA Standardized Laboratoσ☆←λry
Forecast period	2 days	7 days	7 days	7 days	7 days
Applied country	Sweden, Switzerland, Germany	United States, Germany, Switzerland	United States, Germany, Switzerland	United States	United States

Prognosis evaluation system↕δ service object

For the patient
1. Provide information for the patient before £±'deciding whether to t£¶reat
2. Help the patient to partici€>±&pate in the formulat÷±✘ion

For the urologist
1. Provide a more accurate treatment plan
2. Avoid overtreatment or undertrΩ ≥eatment
3. Discuss the treatment plan for the patient Proβ♠δvide strong support

For pathologists
1. Balance the subjectivity of Gleason I≥₽<ndex
2. Enhance pathological assess®∑σ>ment information

Product Category

Prostate cancer genetic★γ♦ testing prognosis risk assessment system (Pros∑®♣tatype® testing system)

熱(rè)烈歡迎百色市(shì)常務副市(shì)長(cháng)石國(gu↔"ó)懷、坪山(shān)區(qū)委書(shū)記陶永欣、區(qū)☆✘≠長(cháng)李勇、副區(qū)長(c≤δ↕háng)陳華平莅臨我司考察

喜訊 | 我司獲廣東(dōng)省科(kē)技(jì)進步二等獎

喜訊！深圳億立方生(shēng)物(wù)新冠試劑獲CE認證

抗疫戰役中誕生(shēng)的(de)先鋒隊-深圳市凱聯生物技術有限公司黨支部

1.5 hours!ONE STEP screening o∞≠δf 18 respiratory pathog₽™ens！

Prostate cancer genetic★γ♦ testing prognosis risk assessment system (Pros∑®♣tatype® testing system)

熱(rè)烈歡迎百色市(shì)常務副市(shì)長(cháng)石國(gu↔"ó)懷、坪山(shān)區(qū)委書(shū)記陶永欣、區(qū)☆✘≠​長(cháng)李勇、副區(qū)長(c≤δ↕háng)陳華平莅臨我司考察

喜訊 | 我司獲廣東(dōng)省科(kē)技(jì)進步二等獎

喜訊！深圳億立方生(shēng)物(wù)新冠試劑獲CE認證

抗疫戰役中誕生(shēng)的(de)先鋒隊-深圳市凱聯生物技術有限公司黨支部

1.5 hours!ONE STEP screening o∞≠δf 18 respiratory pathog₽™ens！

熱(rè)烈歡迎百色市(shì)常務副市(shì)長(cháng)石國(gu↔"ó)懷、坪山(shān)區(qū)委書(shū)記陶永欣、區(qū)☆✘≠長(cháng)李勇、副區(qū)長(c≤δ↕háng)陳華平莅臨我司考察